Astellas Pharma was ranked first in the pharmaceuticals sector in the Disclosure Excellence Selection organized by the Securities Analysts Association of Japan. This was the eighth time it had received the award, and it ranked first in 4 of the 5 evaluation categories.
Astellas Pharma was ranked first in the pharmaceuticals sector in the 2026 fiscal year (32nd) Disclosure Excellence Selection conducted by the Securities Analysts Association of Japan. This was the eighth time it had received the award. It ranked first in 4 of the panel’s 5 categories, contributing to its high overall assessment.
In particular, it received higher ratings than the previous year for “management’s IR stance, the functions of the IR department and basic IR approach” and “disclosure of information related to ESG,” which reportedly raised its overall assessment. Details are available on the Securities Analysts Association of Japan’s website.
Naoki Okamura (岡村 直樹), Representative Director, President and CEO, said that the company places importance on disclosing the value of marketed products, making timely and appropriate disclosures of clinical trial results, and providing information on the characteristics of projects under research and development and their social value after launch. He also emphasized the importance of dialogue to promote understanding of the growth strategy set out in Management Plan 2026.
Following the award, Astellas Pharma said it would deepen dialogue with stakeholders and work to achieve appropriate market valuations and enhance the depth and quality of its disclosures. It also directs readers to related information on its official website and in its press releases.